Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy

• Published in: Signal transduction and targeted therapy Vol. 6; no. 1; pp. 367 - 16
• Main Authors: Li, Xia, Shao, Mi, Zeng, Xiangjun, Qian, Pengxu, Huang, He
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.10.2021; Nature Publishing Group
• Subjects: 631/250/251; 692/699/249; 692/699/255; Acute Disease; Adverse events; Autoimmune diseases; Autoimmune Diseases - complications; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; Cancer Research; Cell Biology; Chimeric antigen receptors; COVID-19; COVID-19 - complications; COVID-19 - immunology; COVID-19 - therapy; Cytokine Release Syndrome - etiology; Cytokine Release Syndrome - immunology; Cytokine Release Syndrome - therapy; Cytokines; Fever; Graft vs Host Disease - complications; Graft vs Host Disease - immunology; Graft vs Host Disease - therapy; Graft-versus-host reaction; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Inflammation; Influenza; Influenza, Human - complications; Influenza, Human - immunology; Internal Medicine; Medicine; Medicine & Public Health; Neoplasms - complications; Neoplasms - immunology; Neoplasms - therapy; Oncology; Pandemics; Pathology; Review; Review Article; SARS-CoV-2 - immunology; Severe Acute Respiratory Syndrome - complications; Severe Acute Respiratory Syndrome - immunology; Severe Acute Respiratory Syndrome - therapy; Severe acute respiratory syndrome-related coronavirus - immunology; Signal transduction; Signal Transduction - immunology; Stem cell transplantation; Toxicity; Tumors

Cytokine release syndrome (CRS) embodies a mixture of clinical manifestations, including elevated circulating cytokine levels, acute systemic inflammatory symptoms and secondary organ dysfunction, which was first described in the context of acute graft-versus-host disease after allogeneic hematopoie...